Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. News/
  3. Caring & giving/
  4. Tracking Our Citizenship & Sustainability Journey
Citizenship-Sustainability Trading-Card_Blogpost

Tracking Our Citizenship & Sustainability Journey

Perhaps one of the most defining moments in the history of Johnson & Johnson occurred more than 70 years ago when General Robert Wood Johnson, son of one of the Company’s co-founders, wrote Our Credo, outlining our responsibilities to all stakeholders and to the communities in which we live and work. It was 1943, a time when very few even understood or appreciated the importance of corporate responsibility in serving the needs of many groups and contributing to the long-term vitality of a business. This 308-word document has stood the test of time and continues to serve as the guide we try to live by every day. And, it is the essence of what citizenship and sustainability means for Johnson & Johnson.

We see our citizenship and sustainability as more than our social, environmental and economic performance. It is who we are and how we act. Our new Citizenship & Sustainability Annual Report gives us the opportunity to share with our diverse stakeholders the ways we are:

  • Working and partnering with others to advance human health and well-being,
  • Helping to safeguard the planet, and
  • Leading a dynamic and growing business responsibly.

We live in a time where health care is one of the biggest challenges facing society – no other issue is as important or personal. As the world’s largest health care company, we have a responsibility to lead and partner to make significant impact as we continue pursuing our aspiration to help billions of people around the world live longer, healthier and happier lives.

We realize the work we do doesn’t just impact the business and society – it also inspires others to pay it forward. One example of this is reflected in the story of Dr. Dalene von Delft from South Africa who, in 2010, developed a dry cough that just wouldn’t go away. Tests confirmed her fear that she had contracted multi drug-resistant tuberculosis (TB). Through an early access program, also commonly referred to as a compassionate use program, she was able to receive our medicine, bedaquiline (trade named SIRTURO® in the U.S.), as part of her treatment. Following an 18-month, multi-drug treatment regimen, Dr. von Delft was cured. Inspired by her experience, she founded TB Proof, an organization dedicated to bringing awareness of TB among health care workers in South Africa.

The commitment our Company has made in seeking out the best research and development to produce the most effective treatments for these kinds of needs is one of the many aspects of our citizenship and sustainability. It’s knowing that our decisions and actions, no matter in what area of our Company, can influence so much more. Read the report.


Shaun Mickus is Director, Corporate Citizenship at Johnson & Johnson. He works with senior leaders to drive the company’s Citizenship & Sustainability strategy and to ensure implementation across a broad range of corporate responsibility initiatives. He brings more than 20 years of business experience across multiple disciplines, brands and corporate initiatives. Additional information about Shaun can be found here.

More from Johnson & Johnson

5 things we now know about atrial fibrillation

More than 50 million people worldwide are affected by this common type of heart arrhythmia. Learn the facts behind this heart condition, plus one patient’s diagnosis story.

Shockwave: Inside the development of a cutting-edge system to treat coronary artery disease

Johnson & Johnson’s Patrick Stephens explains how innovative technology using ultrasonic acoustic pressure waves has made the treatment of certain types of cardiovascular disease easier for doctors and safer for patients.

What is asthma?

This chronic inflammatory disease causes flareups that make it difficult to breathe. Learn about the two types of asthma, common triggers and how Johnson & Johnson is developing approaches that may lead to better treatments.